Bombay High Court Stays Curia India Licence Suspension Pending Appellate Review by State Minister
The Bombay High Court has put on hold an order suspending the pharmaceutical manufacturing licence of Curia India Private Limited, directing Maharashtra’s Food and Drugs Administration (FDA) Minister to expeditiously decide the company’s statutory appeal.
The regulatory action stemmed from an October 30 order issued by the Joint Commissioner of the Food and Drugs Administration (Chhatrapati Sambhajinagar division), which directed a 21-day suspension of operations at Curia’s manufacturing facility in Waluj. The regulator cited 16 procedural and operational deficiencies under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.
Curia India—a subsidiary of the US-based Curia group that manufactures active pharmaceutical ingredients (APIs) and intermediates—filed an administrative appeal before the State FDA Minister on November 3. Faced with an impending shutdown before the appellate authority could hear the matter, the company approached the High Court seeking interim protection and a time-bound ministerial hearing. A division bench comprising Chief Justice M. C. Tripathi and Justice Advait Sethna held that the suspension order will remain in abeyance until the Minister disposes of the appeal.
Legal Topic
-
Area of Law: Administrative Law / Pharmaceutical Regulatory Law
-
Sub-topic: Statutory Appeals / Interim Relief Against Regulatory Sanctions / Natural Justice
Core Legal Issue
The core legal question was whether a writ court should intervene to grant interim protection staying an immediate administrative penalty when a statutory appeal has already been lodged, but the appellate authority has not yet heard the application for stay or the underlying appeal.
The High Court considered whether enforcing an operational shutdown prior to the disposal of a statutory appeal would cause irreversible prejudice, effectively frustrating the manufacturer's right to an effective administrative remedy.
What Did the Court Decide?
The division bench disposed of the writ petition with specific procedural instructions:
-
Suspension Held in Abeyance: The operation of the October 30 suspension order passed by the Joint Commissioner is stayed pending the conclusion of the ministerial appeal.
-
Timeline for Disposal: The FDA Minister has been directed to hear and decide the appeal on its merits, in accordance with law, preferably by November 25.
-
Ministerial Discretion Preserved: The Court clarified that if Curia India’s appeal is ultimately dismissed, the Minister retains full statutory authority to modify or re-impose the suspension period as deemed appropriate.
-
Adherence to Precedent: The bench noted that the circumstances were identical to an interim order passed by the High Court in January 2024 involving similar regulatory action, finding no justification to deviate from established judicial practice.
Key Legal Points
-
Preserving the Efficacy of Statutory Remedies: An appellant should not be exposed to irreparable operational penalties while a statutorily guaranteed appeal remains pending without an urgent hearing.
-
Balance of Convenience and Irreparable Injury: Immediate plant closures impact third parties—such as factory workers and commercial supply chains—warranting interim breathing space when compliance questions are under ministerial review.
-
Conditional Interim Relief: Granting interim relief against an administrative suspension does not wipe away regulatory findings; it merely defers execution, leaving the appellate forum fully empowered to enforce the sanction if the appeal fails.
-
Judicial Comity and Consistency: Where a coordinate bench has previously charted a procedural path in identical disputes, subsequent benches should adhere to that consistency unless compelling reasons require departure.
Relevant Law
-
Drugs and Cosmetics Act, 1940: Governing the licensing, quality standards, and statutory inspections of drug manufacturing units.
-
Drugs and Cosmetics Rules, 1945: Specifically provisions relating to licence suspension, inspection compliance, and the appellate mechanism available before the State Government against licensing authority orders.
-
Article 226 of the Constitution of India: High Court’s discretionary writ jurisdiction invoked to ensure procedural fairness and prevent administrative injustice.
Arguments of the Parties
Petitioner (Curia India Pvt. Ltd.)
-
Senior counsel representing Curia argued that shutting down the Waluj active pharmaceutical ingredient facility for 21 days would cause severe, irreversible financial and commercial harm, disrupting global supply commitments and impacting roughly 150 factory workers.
-
The company emphasized that it had already exercised its statutory right of appeal on November 3, and cited a January 2024 precedent where the High Court had granted similar interim protection until the minister concluded proceedings.
Respondent (State Government & FDA)
-
Counsel appearing for the State submitted that because the petitioner had already invoked the alternative statutory remedy of appeal before the Minister, parallel proceedings under writ jurisdiction ought not to be entertained.
-
The State maintained that regulatory enforcement under the Drugs and Cosmetics Act is vital to safeguarding public health and quality manufacturing standards, meaning licensing sanctions should not be routinely deferred.
Why Does It Matter?
This ruling provides practical guidance on the interplay between administrative penalties and statutory appeals in highly regulated manufacturing sectors. When regulators issue short-term suspension orders—such as two-to-three-week shutdowns—the period of suspension often expires before an administrative appellate authority even conducts a preliminary hearing.
Without judicial intervention, the statutory right of appeal under the Drugs and Cosmetics Rules risks becoming an empty formality. By ordering the suspension into abeyance while simultaneously setting a strict deadline for the FDA Minister, the High Court established an equitable balance: it protects companies from abrupt operational and workforce disruption without stripping regulatory authorities of their eventual enforcement powers.
Legal Takeaway
A statutory right of appeal is meaningless if the punishment runs its full course before the appeal is heard. Where administrative delay threatens to render an appeal infructuous, constitutional courts will step in to hold the penalty in abeyance and mandate an expedited, reasoned hearing on the merits.
Sources
Primary Source:
-
Curia India Pvt. Ltd. v. State of Maharashtra & Ors., Order dated November 5 (Bombay High Court, Division Bench of Chief Justice M. C. Tripathi and Justice Advait Sethna).
Additional Sources:
-
Report by Times News Network, "Bombay High Court keeps company's drug licence suspension on hold, directs FDA minister to decide on appeal by Nov 25", The Times of India.